Postpartum Depression: Medications Safe During Breastfeeding

TL;DR

• Postpartum depression (PPD) affects roughly 1 in 7 birthing parents and is a treatable medical condition — not a character failing.
• Sertraline and paroxetine are first-line pharmacotherapy during lactation, with relative infant doses (RID) well below the 10% safety threshold.
• Cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT) are effective alone for mild-to-moderate PPD and enhance outcomes when combined with medication.
• Brexanolone (Zulresso) and zuranolone (Zurzuvae) represent a new class of rapid-acting neuroactive steroid treatments; breastfeeding data remain limited.
• Thoughts of self-harm or harm to the infant require immediate emergency evaluation — do not wait for a scheduled appointment.

What Is Postpartum Depression?

Postpartum depression is a major depressive episode with onset during pregnancy or within the first four weeks postpartum (DSM-5 "peripartum onset" specifier), though clinically symptoms often emerge up to 12 months after delivery. It is distinct from the transient "baby blues" — mild mood lability, tearfulness, and irritability that peaks around postpartum day 3–5 and resolves spontaneously within two weeks.

Epidemiology

The prevalence of PPD ranges from 10–20% of postpartum individuals in high-income countries, with higher rates reported in populations facing socioeconomic adversity, inadequate social support, or prior depressive episodes (ACOG Committee Opinion No. 757, 2018). The World Health Organization estimates the global prevalence at approximately 17%, with significant regional variation.

Pathophysiology

The exact mechanism remains incompletely understood, but the leading hypothesis centers on neuroactive steroid withdrawal. During pregnancy, levels of allopregnanolone — a potent positive allosteric modulator of GABA-A receptors — rise approximately 30-fold. After placental delivery, these levels collapse abruptly. In individuals with PPD, the brain appears to inadequately adapt to this neurosteroid withdrawal, resulting in impaired GABAergic signaling. This mechanism directly informed the development of brexanolone and zuranolone.

Additional contributing factors include:

• Hypothalamic-pituitary-adrenal (HPA) axis dysregulation
• Inflammatory cytokine activation
• Estradiol and progesterone fluctuations affecting serotonergic and noradrenergic neurotransmission
• Psychosocial stressors (sleep deprivation, role transition, relationship strain)

Risk Factors

Clinicians should screen with heightened vigilance in patients with a personal or family history of depression, prior PPD episodes, unplanned pregnancy, preterm birth, NICU admission, history of intimate partner violence, or limited social support.

Screening: The Edinburgh Postnatal Depression Scale

Universal screening is the cornerstone of early detection. ACOG recommends screening all perinatal patients at least once during the perinatal period using a validated tool (ACOG Committee Opinion No. 757). The American Academy of Pediatrics (AAP) additionally recommends screening at the 1-, 2-, 4-, and 6-month well-child visits, leveraging the pediatric encounter as a safety net.

The Edinburgh Postnatal Depression Scale (EPDS) is the most widely validated screening instrument. It is a 10-item, self-report questionnaire scored 0–30.

Key clinical point: The EPDS is a screening tool, not a diagnostic instrument. A positive screen should prompt a structured clinical interview to confirm a DSM-5 diagnosis before pharmacotherapy is initiated.

Evidence-Based Pharmacotherapy During Breastfeeding

The central concern for breastfeeding parents is infant drug exposure. The metric used to quantify this is the relative infant dose (RID) — the weight-adjusted infant dose as a percentage of the maternal dose. An RID below 10% is generally considered compatible with breastfeeding (Hale's Medications & Mothers' Milk). Most preferred antidepressants for PPD have an RID well below this threshold.

First-Line Agents: SSRIs

Selective serotonin reuptake inhibitors remain the pharmacological backbone of PPD treatment. Sertraline and paroxetine are the preferred SSRIs during breastfeeding based on the lowest measured infant serum concentrations and the most extensive safety data in the LactMed database (National Library of Medicine).

Sertraline is generally considered the single best-studied antidepressant in lactation. Multiple studies report undetectable or clinically negligible infant serum levels, and no adverse developmental effects have been identified in follow-up studies.

Paroxetine also demonstrates very low RID values. However, it carries considerations around its short half-life (which may cause discontinuation symptoms with missed doses) and its FDA Pregnancy Category D rating for first-trimester teratogenicity — relevant if there is any possibility of subsequent pregnancy.

Comparison of Antidepressants During Lactation

Data from LactMed and Hale's Medications & Mothers' Milk (2023 edition). RID ranges represent pooled estimates across published studies.

Second-Line and Adjunctive Agents

When SSRIs are ineffective or poorly tolerated, serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine or duloxetine may be considered. Duloxetine has a relatively low RID (approximately 0.1–1.1%) but less lactation-specific data than sertraline.

Mirtazapine is occasionally used for PPD with prominent insomnia and appetite loss. Its RID is approximately 1.0–6.3%. Sedation is a notable side effect, and the infant should be monitored for excessive drowsiness.

Tricyclic antidepressants (TCAs), particularly nortriptyline, are a reasonable option when SSRIs and SNRIs fail. They are less commonly prescribed first-line due to their side-effect burden and toxicity in overdose.

Novel Neuroactive Steroids: Brexanolone and Zuranolone

Brexanolone (Zulresso)

Brexanolone, an intravenous formulation of synthetic allopregnanolone, received FDA approval in March 2019 — the first drug specifically approved for PPD. It directly addresses the neurosteroid withdrawal hypothesis by providing exogenous allopregnanolone to restore GABA-A receptor modulation.

Administration: Continuous 60-hour intravenous infusion in a certified healthcare facility under the REMS (Risk Evaluation and Mitigation Strategy) program. Patients require continuous pulse oximetry monitoring due to the risk of excessive sedation and sudden loss of consciousness.

Efficacy: In the pivotal trials (BRX3002 and BRX3003), brexanolone demonstrated a statistically significant reduction in Hamilton Depression Rating Scale (HAM-D) scores at 60 hours compared to placebo, with effects sustained at 30 days.

Breastfeeding considerations: Brexanolone is identical to endogenous allopregnanolone, which is naturally present in breast milk. The FDA label states that breastfeeding is not expected to result in clinically relevant infant exposure. However, practical limitations exist — the 60-hour inpatient infusion may disrupt breastfeeding routines, and the sedation risk may impair a parent's ability to safely care for and feed the infant during treatment.

Zuranolone (Zurzuvae)

Zuranolone, an oral neuroactive steroid, received FDA approval in August 2023 for PPD. It is the first oral medication specifically indicated for this condition.

Administration: 50 mg once daily in the evening with a fatty meal for 14 days.

Efficacy: The SKYLARK trial demonstrated significant improvement in depressive symptoms (measured by HAM-D) at day 15 compared to placebo, with a treatment difference evident as early as day 3.

Zuranolone breastfeeding considerations: This is where the clinical picture becomes more cautious. Zuranolone is not recommended during breastfeeding per the FDA label. Animal studies showed zuranolone was present in milk, and human lactation data are currently insufficient. The prescribing information advises patients to use an alternative feeding method during treatment and for 5 days after the last dose — approximately 5 elimination half-lives.

Clinical note: Neither brexanolone nor zuranolone replaces the need for ongoing treatment in patients with recurrent or chronic depression. They are approved specifically for PPD episodes and may be followed by conventional antidepressant maintenance therapy.

Dosing and Practical Guidance

Starting and Titrating SSRIs for PPD

Practical principles:

• Start low, go slow — but do reach therapeutic doses. Subtherapeutic dosing is the most common prescribing error.
• Allow 4–6 weeks at adequate dose before concluding a trial has failed.
• If the patient was stable on an antidepressant before pregnancy and it has an acceptable lactation profile, restarting the same agent is preferred over switching.
• Time the dose to minimize impact on breastfeeding: for drugs with short half-lives, some clinicians suggest dosing immediately after a feeding, though this strategy has limited evidence for agents with already-low RID values.

The Role of Psychotherapy

Psychotherapy is not merely adjunctive — it is a first-line treatment. ACOG, NICE, and the Canadian guidelines all endorse CBT and IPT as monotherapy for mild-to-moderate PPD.

• Cognitive-behavioral therapy (CBT): Targets maladaptive thought patterns (guilt, catastrophizing, perceived inadequacy). Strong evidence base with NNT (number needed to treat) comparable to antidepressants for mild-to-moderate depression.
• Interpersonal therapy (IPT): Focuses on role transitions, relationship conflicts, and grief — issues particularly salient in the postpartum period. The Cochrane review by Dennis & Hodnett supports its efficacy.

For moderate-to-severe PPD, combined pharmacotherapy and psychotherapy yields superior outcomes to either alone.

Side Effects and Infant Monitoring

Common Maternal Side Effects of SSRIs

• Nausea, diarrhea (typically transient, resolves within 1–2 weeks)
• Insomnia or somnolence
• Sexual dysfunction (may be less relevant acutely postpartum but affects long-term adherence)
• Headache
• Activation/anxiety in the first week — warn patients to prevent premature discontinuation

Monitoring the Breastfed Infant

When a breastfeeding parent is taking an antidepressant, clinicians should counsel on infant monitoring signs:

• Excessive sedation or lethargy — decreased feeding, prolonged sleep
• Irritability, poor feeding, or increased crying — particularly with higher-RID agents
• Weight gain deceleration — monitor at routine pediatric visits
• GI disturbance — diarrhea, vomiting

In practice, adverse infant effects from sertraline or paroxetine at standard maternal doses are exceedingly rare. The decision to breastfeed while taking these medications should factor in the well-established benefits of breastfeeding — the LactMed database and the ABM (Academy of Breastfeeding Medicine) Protocol #18 both support continued breastfeeding with preferred agents.

Contraindications, Interactions, and Cautions

Special Populations

Adolescent Parents

Adolescent mothers face disproportionately high PPD rates. SSRI prescribing in adolescents carries the FDA black-box warning regarding suicidality in individuals under 25 — this does not preclude use but mandates closer monitoring, particularly in the first 4–8 weeks. The benefit of treating moderate-to-severe PPD typically outweighs this risk.

Parents with Substance Use Disorders

PPD is highly comorbid with substance use. Sertraline remains a reasonable choice and has no significant interaction with buprenorphine or methadone maintenance therapy. Avoid paroxetine in patients taking methadone due to CYP2D6 inhibition potentially increasing methadone levels.

History of Severe PPD or Postpartum Psychosis

Patients with prior postpartum psychosis require a predelivery psychiatric plan. This population typically needs mood stabilizers or antipsychotics rather than antidepressant monotherapy, and the pharmacotherapy choice must balance lactation safety with relapse prevention. Quetiapine and olanzapine have moderate lactation data; lithium requires close infant monitoring of serum levels and thyroid function.

Partners and Non-Birthing Parents

Depression in the postpartum period also affects partners at rates of approximately 8–10%. While the neuroendocrine mechanism differs, the same pharmacotherapy principles apply, without the lactation safety considerations.

Red Flags — When to Seek Immediate Care

The following presentations constitute psychiatric emergencies and require same-day evaluation:

• Suicidal ideation — passive ("everyone would be better off without me") or active (plan, intent, means)
• Infanticidal thoughts — intrusive thoughts of harming the baby, particularly if ego-syntonic (not distressing to the patient)
• Psychotic features — hallucinations (especially command auditory hallucinations), delusions, paranoia, disorganized behavior
• Severe functional impairment — inability to eat, sleep, or care for self or infant for ≥ 24 hours
• Acute agitation or catatonia

Postpartum psychosis is a distinct emergency occurring in approximately 1–2 per 1,000 deliveries, most commonly within the first two weeks postpartum. It requires immediate inpatient psychiatric hospitalization. Risk factors include bipolar disorder (particularly bipolar I) and prior postpartum psychosis.

Hospitalization Criteria for PPD

Voluntary or involuntary psychiatric admission should be considered when:

• The patient expresses active suicidal or homicidal ideation with plan or intent
• Psychotic symptoms are present
• The patient is unable to maintain basic self-care or infant care
• Outpatient treatment has failed to stabilize acute risk
• The home environment is unsafe

Frequently Asked Questions

Will taking sertraline while breastfeeding harm my baby?

Based on extensive published data and LactMed reviews, sertraline at standard doses results in very low infant exposure (RID 0.4–2.2%). Multiple studies measuring infant serum concentrations have found undetectable or clinically insignificant levels. No adverse developmental outcomes attributable to sertraline exposure through breast milk have been identified. Both ACOG and the Academy of Breastfeeding Medicine consider sertraline compatible with breastfeeding.

How long does postpartum depression medication take to work?

Traditional antidepressants (SSRIs, SNRIs) typically require 2–4 weeks for initial symptom improvement, with full therapeutic effect at 6–8 weeks. The novel neuroactive steroids act faster — brexanolone within 24–48 hours and zuranolone within approximately 3 days — but they are not universally accessible due to cost and logistical constraints.

Can I stop my antidepressant once I feel better?

Premature discontinuation is the leading cause of PPD relapse. Guidelines generally recommend maintaining antidepressant therapy for at least 6–12 months after achieving remission, followed by a gradual taper over 4 or more weeks. Patients with recurrent depressive episodes may need longer or indefinite maintenance. Never stop abruptly — taper under clinician supervision.

Is zuranolone safe for breastfeeding?

Currently, zuranolone is not recommended during breastfeeding. The FDA prescribing information advises using alternative feeding methods during the 14-day treatment course and for 5 days afterward. Human milk transfer data are not yet available. This remains an active area of research.

What if I don't want to take medication?

Psychotherapy — particularly CBT and IPT — is an effective first-line treatment for mild-to-moderate PPD. Other evidence-supported strategies include structured exercise (30 minutes of moderate activity most days), adequate sleep optimization (though challenging with a newborn), and peer support programs. If symptoms are severe, however, medication significantly improves outcomes and should be strongly considered.

Can I take my pre-pregnancy antidepressant while breastfeeding?

In many cases, yes. If you were stable on an antidepressant before or during pregnancy, continuing or resuming the same agent is often preferred — provided it has an acceptable lactation profile. Switching medications introduces a period of vulnerability. Discuss the specific agent's RID and lactation data with your prescriber.

Does PPD go away on its own?

Some mild cases resolve spontaneously, but untreated moderate-to-severe PPD can persist for months to years and is associated with impaired maternal-infant bonding, adverse child developmental outcomes, and increased risk of chronic depressive illness. Early, adequate treatment produces the best outcomes for both parent and child.

How is PPD different from "baby blues"?

Baby blues affect up to 80% of postpartum individuals, begin within 2–3 days of delivery, and resolve by 2 weeks without treatment. PPD involves persistent depressive symptoms lasting more than 2 weeks, functional impairment, and often features prominent anxiety, guilt, sleep disruption beyond what the infant's schedule causes, and diminished interest in the baby. If symptoms persist beyond 2 weeks or include thoughts of self-harm, screening and clinical evaluation are warranted.

References

1. ACOG Committee Opinion No. 757: Screening for Perinatal Depression. Obstetrics & Gynecology 2018;132(5):e208–e212.

2. Drugs and Lactation Database (LactMed). National Library of Medicine. Bethesda, MD. Available at: toxnet.nlm.nih.gov. [Updated continuously.]

3. Hale TW. Hale's Medications & Mothers' Milk 2023. 20th ed. New York: Springer Publishing; 2023.

4. Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 2018;392(10152):1058–1070. PMID: 30177236.

5. Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the treatment of postpartum depression. American Journal of Psychiatry 2023;180(9):668–675. PMID: 37552687.

6. Dennis CL, Hodnett E. Psychosocial and psychological interventions for treating postpartum depression. Cochrane Database of Systematic Reviews 2007;(4):CD006116.

7. Wisner KL, Perel JM, Peindl KS, et al. Prevention of postpartum depression: a pilot randomized clinical trial. American Journal of Psychiatry 2004;161(7):1290–1292. PMID: 15229064.

8. Berle JO, Spigset O. Antidepressant use during breastfeeding. Current Women's Health Reviews 2011;7(1):28–34.

9. Academy of Breastfeeding Medicine. ABM Clinical Protocol #18: Use of Antidepressants in Breastfeeding Mothers. Breastfeeding Medicine 2015;10(6):290–299. PMID: 26204124.

10. NICE Guideline CG192: Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance. National Institute for Health and Care Excellence; updated 2020.

11. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry 1987;150:782–786. PMID: 3651732.

About the Author

Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in pharmacotherapy optimization, medication safety, and patient education. He has practiced across hospital, community, and consultative pharmacy settings with particular expertise in psychopharmacology and perinatal medication management. Dr. Ozarchuk writes for PillsCard.com to bridge the gap between clinical evidence and the information patients and caregivers need to make informed decisions about their treatment.

Medical Disclaimer

This article is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The content should not replace a consultation with a qualified healthcare provider. Always seek the advice of your physician, psychiatrist, or other qualified health professional with any questions regarding a medical condition or medication. Never disregard professional medical advice or delay seeking it because of information you have read on this website. If you are experiencing a medical or psychiatric emergency — including thoughts of self-harm or harm to your child — contact your local emergency services or go to the nearest emergency department immediately.